Janux Therapeutics
JANX
57 hedge funds and large institutions have $354M invested in Janux Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 6 closing their positions.
500% more call options, than puts
Call options by funds: $24K | Put options by funds: $4K
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
6% more funds holding
Funds holding: 54 → 57 (+3)
3.16% more ownership
Funds ownership: 72.94% → 76.1% (+3.2%)
2% less capital invested
Capital invested by funds: $362M → $354M (-$8.13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.71M |
| 4 |
O
OrbiMed
New York
|
+$5.55M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$5.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.37M |
| 2 |
Cerity Partners
New York
|
-$723K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$595K |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$483K |
| 5 |
Millennium Management
New York
|
-$434K |
JANX Hedge Fund Activity: Q3 2023 in Review
57 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2023, worth a combined $354M — down 2.2% from $362M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new JANX positions and 6 closed out — a net gain of 3 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $15.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.37M sold.
- 57 institutional investors held Janux Therapeutics (JANX) as of Q3 2023, up from 54 in Q2 2023.
- Funds reported $354M of Janux Therapeutics stock for Q3 2023, down 2.2% quarter-over-quarter.
- 9 funds opened new Janux Therapeutics positions in Q3 2023 and 6 closed out, a net change of +3 holders.
- The largest Janux Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $15.2M added.
- The largest Janux Therapeutics seller in Q3 2023 was EcoR1 Capital, an estimated $5.37M sold.
Based on aggregated 13F filings for Q3 2023.